Yahoo
Jakarta - Delayed Quote IDR

PT Kalbe Farma Tbk. (KLBF.JK)

720.00 -10.00 (-1.37%)
At close: 4:06:13 PM GMT+7
Chart Range Bar
Loading chart for KLBF.JK
  • Previous Close 730.00
  • Open 730.00
  • Bid --
  • Ask --
  • Day's Range 715.00 - 735.00
  • 52 Week Range 630.00 - 1,320.00
  • Volume 30,279,500
  • Avg. Volume 71,323,052
  • Market Cap (intraday) 32.579T
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 9.07
  • EPS (TTM) 79.41
  • Earnings Date (est.) --
  • Forward Dividend & Yield 20.00 (2.74%)
  • Ex-Dividend Date Jun 4, 2026
  • 1y Target Est 1,119.44

PT Kalbe Farma Tbk., together with its subsidiaries, engages in the development, manufacture, and trading of pharmaceutical products in Indonesia. It operates through Prescription Pharmaceuticals; Consumer Health; Nutritionals; and Distribution and Logistic segments. The company provides prescription/ethical; consumer health; nutritionals; distribution and logistics; health services; medical devices; biopharma; animal health; international business, and E-health products. In addition, the company provides health screening services; operates as an agent and representative for biotechnology products; distributes consumer products, medical equipment, cosmetics, and other trading products; and trades in medical and laboratory equipment and supplies, raw materials for pharmaceutical products, and consumable products for hemodialysis therapy, as well as offers advertising services. The company was incorporated in 1966 and is headquartered in Jakarta, Indonesia.

www.kalbe.co.id

10,879

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 11/2/2026, which may include dividends or other distributions. Benchmark is IDX COMPOSITE (^JKSE) .

YTD Return

KLBF.JK
38.57%
IDX COMPOSITE (^JKSE)
41.06%

1-Year Return

KLBF.JK
41.94%
IDX COMPOSITE (^JKSE)
37.57%

3-Year Return

KLBF.JK
51.51%
IDX COMPOSITE (^JKSE)
24.51%

5-Year Return

KLBF.JK
50.33%
IDX COMPOSITE (^JKSE)
21.51%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 9.5T
Earnings 817.43B
Profit Margin 8.61%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

0
2T
4T
6T
8T
0.0%
2.0%
4.0%
6.0%
8.0%

Analyst Insights

View More

Analyst Price Targets

820.00
1,119.44 Average
720.00 Current
1,700.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    9.84%

  • Return on Assets (ttm)

    9.42%

  • Return on Equity (ttm)

    15.13%

  • Revenue (ttm)

    38.31T

  • Net Income Avi to Common (ttm)

    3.77T

  • Diluted EPS (ttm)

    79.41

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    5.42T

  • Total Debt/Equity (mrq)

    1.11%

  • Levered Free Cash Flow (ttm)

    1.83T

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: